D
Aerovate Therapeutics, Inc.
AVTE
$2.49
-$0.02-0.80%
D
Sell
1/22/2025Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index and total return index.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index and total return index.
E
Sell
1/7/2025Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 1/7/2025 due to a decline in the volatility index.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 1/7/2025 due to a decline in the volatility index.
D
Sell
12/9/2024Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 12/9/2024 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.8616 to -$0.5625, EBIT increased 33.46% from -$26.17M to -$17.41M, and operating cash flow increased 21.48% from -$20.43M to -$16.04M.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 12/9/2024 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.8616 to -$0.5625, EBIT increased 33.46% from -$26.17M to -$17.41M, and operating cash flow increased 21.48% from -$20.43M to -$16.04M.
E
Sell
8/21/2024Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 8/21/2024 due to a major decline in the total return index, growth index and volatility index. EBIT declined 6.28% from -$24.62M to -$26.17M, and earnings per share declined from -$0.8342 to -$0.8616.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 8/21/2024 due to a major decline in the total return index, growth index and volatility index. EBIT declined 6.28% from -$24.62M to -$26.17M, and earnings per share declined from -$0.8342 to -$0.8616.
D
Sell
7/3/2024Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 7/3/2024 due to an increase in the valuation index.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E+ on 7/3/2024 due to an increase in the valuation index.
E
Sell
6/18/2024Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 6/18/2024 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 59.95% from -$14.8M to -$23.67M, earnings per share declined from -$0.7371 to -$0.8342, and EBIT declined 11.57% from -$22.07M to -$24.62M.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E+ from D- on 6/18/2024 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 59.95% from -$14.8M to -$23.67M, earnings per share declined from -$0.7371 to -$0.8342, and EBIT declined 11.57% from -$22.07M to -$24.62M.
D
Sell
3/14/2023Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and solvency index. The quick ratio declined from 40.47 to 18.5.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and solvency index. The quick ratio declined from 40.47 to 18.5.
D
Sell
7/1/2022Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D from D- on 7/1/2022 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 56.76% from -$13.09M to -$5.66M.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D from D- on 7/1/2022 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 56.76% from -$13.09M to -$5.66M.
D
Sell
3/2/2022Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E on 03/02/2022.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to D- from E on 03/02/2022.
E
Sell
12/16/2021Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E from E+ on 12/16/2021 due to a decline in the volatility index.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E from E+ on 12/16/2021 due to a decline in the volatility index.
E
Sell
12/1/2021Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to E+ from E on 12/1/2021 due to a significant increase in the solvency index, growth index and efficiency index. The quick ratio increased from 14.11 to 47.29, total capital increased 209.83% from $58.24M to $180.45M, and earnings per share increased from -$23.795 to -$0.2589.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to E+ from E on 12/1/2021 due to a significant increase in the solvency index, growth index and efficiency index. The quick ratio increased from 14.11 to 47.29, total capital increased 209.83% from $58.24M to $180.45M, and earnings per share increased from -$23.795 to -$0.2589.
E
Sell
11/3/2021Upgraded
Aerovate Therapeutics, Inc. (AVTE) was upgraded to E from E- on 11/3/2021 due to an increase in the volatility index.
Aerovate Therapeutics, Inc. (AVTE) was upgraded to E from E- on 11/3/2021 due to an increase in the volatility index.
E
Sell
10/15/2021Downgrade
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E- from E on 10/15/2021 due to a decline in the volatility index.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E- from E on 10/15/2021 due to a decline in the volatility index.
E
Sell
9/23/2021None
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E from U on 09/23/2021.
Aerovate Therapeutics, Inc. (AVTE) was downgraded to E from U on 09/23/2021.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
